Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma

Summary

The primary purpose of this phase II clinical trial is to determine the safety and effect on survival of patients autologous dendritic cells pulsed with autologous tumor lysate as a treatment for low-grade glioma patients. Other goals of this study are to determine if the vaccine can cause an immune response against patients' cancer cells and slow the growth of their brain tumors

Timeline

Start

2012-01-10

Primary completion

2016-05-13

Completion

2016-05-13

Drugs

Indications